Avanafil
FDA-approved product (tablet, oral), marketed as Avanafil, Stendra.
- Registered studies
- 24
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Erectile dysfunction
- Impotence
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Drugs used in erectile dysfunction
- FDA pharmacologic class
- Phosphodiesterase 5 Inhibitor FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA54.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli40.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae27.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis53.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
24registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Avanafil with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- UrsodiolExisting use: Biliary liver cirrhosis, Primary biliary cirrhosis69.2% AI-predicted activityagainst MRSA50+ registered studies
- OlaparibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 9 more69.2% AI-predicted activityagainst MRSA50+ registered studies
- Ganirelix AcetateExisting use: Female infertility, Positive regulation of ovulation, Reproductive Techniques, Assisted69.1% AI-predicted activityagainst MRSA50+ registered studies
- DanicopanExisting use: Acquired paroxysmal nocturnal hemoglobinuria, Hemoglobinuria, Paroxysmal, Hemolysis68.7% AI-predicted activityagainst MRSA30 registered studies
- Simeprevir SodiumExisting use: Chronic hepatitis C virus infection68.6% AI-predicted activityagainst MRSANo documented evidence found
- Lanreotide AcetateExisting use: Acromegaly, Carcinoid syndrome68.3% AI-predicted activityagainst MRSA50+ registered studies
- Cholic AcidExisting use: Abnormality of the gastrointestinal tract, Inborn errors of metabolism, Liver disease and 1 more68.0% AI-predicted activityagainst MRSA50+ registered studies
- EptifibatideExisting use: Acute coronary syndrome, Acute myocardial infarction, Intermediate coronary syndrome and 2 more67.8% AI-predicted activityagainst MRSA35 registered studies
- AbarelixExisting use: Neoplasm67.7% AI-predicted activityagainst MRSA5 registered studies
- EverolimusExisting use: Adenoma sebaceum, Anaplastic astrocytoma, Angiomyolipoma and 18 more67.5% AI-predicted activityagainst MRSA50+ registered studies
- Paliperidone PalmitateExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.3% AI-predicted activityagainst MRSA50+ registered studies
- PaliperidoneExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.2% AI-predicted activityagainst MRSA50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
A Pharmacokinetic Study of Avanfil in Healthy Young Male Subjects
NCT00914511 · start 2009-05
Registered record
- Registry ID
- NCT00914511
- Conditions
- Avanfil ADME; Semen Exposure; Sperm Function
- Interventions
- avanafil 200mg; avanafil 200mg
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2009-05
- Completion
- 2009-06
- Enrolment
- 32
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAvanfil ADME; Semen Exposure; Sperm FunctionInterventionavanafil 200mg; avanafil 200mgPhasePhase 1Registry statusCompletedResearch Evaluating an Investigational Medication for Erectile Dysfunction - Post-Prostatectomy
NCT00895011 · start 2009-04
Registered record
- Registry ID
- NCT00895011
- Conditions
- Erectile Dysfunction
- Interventions
- Placebo; Avanafil; Avanafil
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2009-04
- Completion
- 2011-04
- Enrolment
- 298
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionErectile DysfunctionInterventionPlacebo; Avanafil; AvanafilPhasePhase 3Registry statusCompletedLong-Term Safety and Efficacy Study of Avanafil in Men With Erectile Dysfunction
NCT00853606 · start 2009-03
Registered record
- Registry ID
- NCT00853606
- Conditions
- Erectile Dysfunction
- Interventions
- avanafil
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2009-03
- Completion
- 2010-04
- Enrolment
- 712
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionErectile DysfunctionInterventionavanafilPhasePhase 3Registry statusCompletedTherapeutic Confirmatory Study to Evaluate the Efficacy and Safety of Avanafil
NCT00903981 · start 2009-03
Registered record
- Registry ID
- NCT00903981
- Conditions
- Erectile Dysfunction
- Interventions
- Avanafil; Avanafil; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2009-03
- Completion
- 2009-11
- Enrolment
- 208
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionErectile DysfunctionInterventionAvanafil; Avanafil; PlaceboPhasePhase 3Registry statusCompletedResearch Evaluating an Investigational Medication for Erectile Dysfunction - Diabetic ED (REVIVE-D)
NCT00809471 · start 2008-12
Registered record
- Registry ID
- NCT00809471
- Conditions
- Erectile Dysfunction
- Interventions
- placebo; avanafil; avanafil
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2008-12
- Completion
- 2010-02
- Enrolment
- 390
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionErectile DysfunctionInterventionplacebo; avanafil; avanafilPhasePhase 3Registry statusCompletedResearch Evaluating an Investigational Medication for Erectile Dysfunction - General ED
NCT00790751 · start 2008-11
Registered record
- Registry ID
- NCT00790751
- Conditions
- Erectile Dysfunction
- Interventions
- placebo; avanafil; avanafil; avanafil
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2008-11
- Completion
- 2009-08
- Enrolment
- 646
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionErectile DysfunctionInterventionplacebo; avanafil; avanafil; avanafilPhasePhase 3Registry statusCompletedA Thorough EKG Safety Study of TA-1790 (Avanafil)
NCT00769041 · start 2008-10
Registered record
- Registry ID
- NCT00769041
- Conditions
- Erectile Dysfunction
- Interventions
- moxifloxacin; avanafil; avanafil; sugar pill
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2008-10
- Completion
- 2009-01
- Enrolment
- 57
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionErectile DysfunctionInterventionmoxifloxacin; avanafil; avanafil; sugar pillPhasePhase 1Registry statusCompletedTo Evaluate The Effect Of Ketoconazole, Ritonavir and Erythromycin on the Safety and Pharmacokinetics of Avanafil
NCT00770042 · start 2008-10
Registered record
- Registry ID
- NCT00770042
- Conditions
- Erectile Dysfunction
- Interventions
- Ritonavir; Ketoconazole; Erythomycin; Avanafil; Avanafil; Avanafil
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2008-10
- Completion
- 2008-12
- Enrolment
- 44
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionErectile DysfunctionInterventionRitonavir; Ketoconazole; Erythomycin; Avanafil +2 morePhasePhase 1Registry statusCompletedEfficacy and Safety of Avanafil in the Patients With Erectile Dysfunction
NCT02477436 · start 2008-02
Registered record
- Registry ID
- NCT02477436
- Conditions
- Erectile Dysfunction
- Interventions
- Avanafil; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2008-02
- Completion
- 2008-09
- Enrolment
- 159
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionErectile DysfunctionInterventionAvanafil; PlaceboPhasePhase 2Registry statusCompleted